Dymicron® is a pioneering medical technology company focused on transforming the field of musculoskeletal health. At the core of our innovation is Adymite™ polycrystalline diamond—one of the strongest and most wear-resistant materials known to man. Adymite is a Dymicron proprietary, patented material. Dymicron is the only company with polycrystalline diamond technology for human interbody applications.
Triadyme®-C, our flagship cervical artificial disc made with Adymite, is engineered for unmatched durability and performance in cervical total disc replacement surgery. As one of the hardest substances known to man, Adymite provides extreme durability and an ultra-low coefficient of friction. This helps Triadyme-C resist the wear, breakdown, and debris release that may limit the lifespan and safety of traditional disc replacement devices.
Strong First Half Sets the Stage for Growth
As we reach the midpoint of 2026, Dymicron continues to achieve significant milestones that strengthen our position and advance our mission to revolutionize cervical disc replacement. During the first six months of the year, we continue to enroll patients in the United States Triadyme-C IDE clinical trial, building momentum in bringing our innovative technology to the U.S. market. We also hosted a highly successful Expert Meeting in Germany, bringing together leading spine surgeons to share clinical experience and insights from years of Triadyme-C international use. Further strengthening our leadership and strategic guidance, we welcomed renowned spine industry executive Peter Wehrly to our Board of Directors. These accomplishments reflect the dedication of our team, the growing enthusiasm surrounding Triadyme-C, and the strong foundation we are building for continued growth in the second half of the year.
Dymicron Continues to Enroll Patients in the Triadyme-C IDE Clinical Trials
Dymicron continues to make progress in its U.S. Triadyme-C IDE clinical trial, with patient enrollment advancing to 8 patients. Following the successful enrollment of the first patient earlier this year, our leading investigator remains actively engaged in identifying and enrolling qualified candidates.
The IDE study is a critical step in generating the clinical evidence needed to support future regulatory and commercialization objectives in the United States. As enrollment progresses, Dymicron remains focused on working closely with our investigators to ensure efficient trial execution while maintaining the highest standards of patient care and data quality.
We are encouraged by the momentum we are seeing and remain committed to advancing the Triadyme-C program toward key clinical and regulatory milestones. We look forward to providing additional enrollment updates and sharing future achievements as the study continues to advance.
Image: Triadyme-C Artificial Disc
Image: Triadyme-C Post-Op X-ray
Image: Triadyme-C in the Spine
First DACH Expert Meeting Strengthens Clinical Collaboration
Image: Dr. David Harding, Dr. Dirk Dorian Selter, Dr. Ardeshir Ardeshiri, Prof. Dr. Robert Pflugmacher, Prof. Dr. Hans-Joachim Wilke, Dr. Ulrike Laupichler, Alan Layton, Eric Lange, Jeff Bennett, Prof. Dr. Christoph Mehren, Dr. Ardavan Ardeshiri
Dymicron hosted its first Expert Meeting for the Germany, Austria, and Switzerland (DACH) region, bringing together leading spine surgeons in Munich to share clinical experiences, discuss emerging trends in cervical disc arthroplasty, and explore the future of motion-preservation for the cervical spine.
This meeting provided a valuable forum for peer-to-peer collaboration and clinical exchange, reinforcing Dymicron's commitment to advancing cervical artificial disc technology through innovation, education, clinical insight, and evidence-based medicine.
We extend our sincere thanks to Dr. Ardavan Ardeshiri for hosting this extraordinary event and to Dr. Ulrike Laupichler for moderating the inspirational discussions.
The strong engagement and clinical insights shared throughout the expert meeting underscore the growing interest in next-generation cervical artificial disc technologies and the critical role these technologies play in improving future patient outcomes.
Peter Wehrly Joins Dymicron Board of Directors
Dymicron strengthened its leadership team during the first half of 2026 with the appointment of Peter Wehrly to its Board of Directors.
A respected MedTech executive, Peter brings 40+ years of experience leading global medical device organizations, including Synaptive Medical, Medtronic, Johnson & Johnson, Cpvidian, Titan Spine, and others.
Image: Peter Wehrly, Member of the Board of Directors
Throughout his career, he has played a pivotal role in driving innovation, building high-performing organizations, advancing clinical evidence programs, and commercializing transformative technologies worldwide.
As Dymicron continues to advance the Triadyme-C Cervical Artificial Disc through its U.S. IDE study and toward PMA approval, Peter's expertise in regulatory strategy, commercialization, and global market development will provide valuable guidance in the company's next phase of growth.
We are honored to welcome Peter to the Board and look forward to benefiting from his leadership and strategic insight as we continue to execute on our vision.
Image: Ardavan Ardeshiri, MD, presenting at SSA Meeting
Recent Clinical Data Presented at Spine Meeting in Australia
Dymicron's innovative Triadyme-C Cervical Artificial Disc was featured at the Spine Society of Australia Annual Meeting, where Dr. Ardavan Ardeshiri presented one-year clinical and radiographic outcomes for patients treated with Triadyme-C.
We thank Dr. Ardeshiri for his leadership and contributions to advancing the conversation surrounding next-generation cervical disc replacement.
Expanding Access Through Global Partnerships
Dymicron continues to expand access to Triadyme-C through strategic partnerships around the world. In Latin America and the Caribbean, Heca Global serves as Dymicron's distribution partner, leveraging its presence across 17 countries and expertise in regulatory, reimbursement, medical education, and commercial operations.
Together, Dymicron and Heca Global are advancing the adoption of next-generation cervical disc replacement technology and expanding access to motion-preserving care for patients throughout the region.
Dymicron Sponsors SPINEMarketGroup
Dymicron is proud to sponsor SPINEMarketGroup (SMG) in 2026, one of the most respected platforms connecting the global spine community. With a reach of more than 50,000 spine surgeons, industry leaders, and distributors worldwide, this partnership supports Dymicron's continued commitment to increase awareness of Triadyme-C and engage with key stakeholders across the global spine market.
Questions
To contact Investor Relations, please send a message or call: Curt Ence Chief FInancial Officer Email: IR@dymicron.com
